Advertisement

Der Onkologe

, Volume 25, Issue 12, pp 1110–1117 | Cite as

Komplementärmedizinische Behandlungsansätze bei Inappetenz und Ösophagitis

  • Judith BüntzelEmail author
  • Jutta Hübner
  • Jens Büntzel
Integrative Onkologie
  • 63 Downloads

Zusammenfassung

Hintergrund

Für viele Patienten mit HNO-, Ösophagus- und Bronchialkarzinomen stellen Ösophagitis und Inappetenz ein erhebliches Problem dar. Beides hat einen tiefgreifenden Einfluss auf den Ernährungsstatus der Patienten.

Methode

Klinisch bereits geprüfte komplementärmedizinische Behandlungsansätze wurden Zusammengestellt. Es erfolgt eine ergänzende Auflistung phytotherapeutischer Möglichkeiten aus dem Kanon der Traditionellen Europäischen Medizin (TEM).

Ergebnisse

Sowohl zur Behandlung der Inappetenz als auch der Ösophagitis gibt es eine Reihe medikamentöser und nichtmedikamentöser Behandlungsansätze, die der Onkologe kennen und beachten sollte. Europäische Phytotherapeutika sind bisher relativ selten einer klinischen Prüfung unterzogen worden.

Schlussfolgerungen

Die Nutzung komplementärmedizinischer Maßnahmen kann sowohl bei Appetitverlust als auch bei Ösophagitis im Einzelfall sinnvoll sein. Forschungsbedarf besteht insbesondere auf dem Gebiet der traditionellen europäischen Heilkräuter, da diese eine hohe Akzeptanz bei den Patienten haben.

Schlüsselwörter

Appetitverlust HNO-, Ösophagus- und Bronchialkarzinome Tumorpatienten Phytotherapie Traditionelle Europäische Medizin 

Complementary medical treatment approaches for patients with loss of appetite and esophagitis

Abstract

Background

Many patients with head, neck, bronchial or esophageal cancer suffer from loss of appetite and/or esophagitis due to multimodal treatment. Both symptoms have an important impact on the nutritional status of these patients.

Method

Compilation of several approaches of complementary alternative medicine (CAM), which were tested in clinical studies. Additionally, known phytopharmaceutical remedies from traditional European herbal medicine were listed.

Results

There are several drug-based and nonpharmaceutical therapeutic approaches for treating acute esophagitis and loss of appetite, which an oncologist should know and consider for treatment. So far there are only very few clinical studies investigating traditional European phytopharmaceutical drugs.

Conclusion

The use of CAM measures for improving appetite or inflammation of the esophagus can be reasonable in individual cases. More in-depth investigations of the effects of traditional European medicinal herbs are required as patients show a high consumer acceptance for these remedies.

Keywords

Loss of appetite Head, neck, bronchial or esophageal cance Tumor patients Phytotherapy Traditional European herbal medicine 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

J. Büntzel, J. Hübner und J. Büntzel geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Büntzel J, Hübner J, Büntzel J (2019) Komplementärmedizinische Behandlungsansätze bei oraler Mukositis und Xerostomie. Onkologe 25:269–274.  https://doi.org/10.1007/s00761-019-0521-5 CrossRefGoogle Scholar
  2. 2.
    Büntzel J, Hübner J, Steinau P, Büntzel J (2019) Komplementärmedizinische Behandlungsansätze bei Verlust des Riechens und Schmeckens. Onkologe 25:615–620.  https://doi.org/10.1007/s00761-019-0590-5 CrossRefGoogle Scholar
  3. 3.
    Leitlinienprogramm Onkologie (2019) Supportive Therapie. https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/. Zugegriffen: 11. Nov. 2018Google Scholar
  4. 4.
    Muscaritoli M, Molfino A, Scala F et al (2019) Nutritional and metabolic derangements in Mediterranean cancer patients and survivors: the ECPC 2016 survey. J Cachexia Sarcopenia Muscle 10:517–525.  https://doi.org/10.1002/jcsm.12420 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Davis MP, Panikkar R (2018) Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med 8:86–101CrossRefGoogle Scholar
  6. 6.
    Zhang F, Shen A, Jin Y, Qiang W (2018) The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. BMC Complement Altern Med 18:236.  https://doi.org/10.1186/s12906-018-2304-8 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ruiz-García V, López-Briz E, Carbonell-Sanchis R et al (2018) Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle 9:444–452.  https://doi.org/10.1002/jcsm.12292 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Büntzel J, Küttner K (1995) Value of megestrol acetate in treatment of cachexia in head-neck tumors. Laryngorhinootologie 74:504–507.  https://doi.org/10.1055/s-2007-997789 CrossRefGoogle Scholar
  9. 9.
    Miller S, McNutt L, McCann M‑A, McCorry N (2014) Use of corticosteroids for anorexia in palliative medicine: a systematic review. J Palliat Med 17:482–485.  https://doi.org/10.1089/jpm.2013.0324 CrossRefGoogle Scholar
  10. 10.
    European Medicines Agency (2017) Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride). https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-adlumiz-anamorelin-hydrochloride_en.pdf. Zugegriffen: 24.10.2019Google Scholar
  11. 11.
    Guo Q, Li Q, Wang J et al (2019) A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. Medicine (Baltimore) 98:e16234.  https://doi.org/10.1097/MD.0000000000016234 CrossRefGoogle Scholar
  12. 12.
    Kouchaki B, Janbabai G, Alipour A et al (2018) Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. Support Care Cancer 26:2479–2489.  https://doi.org/10.1007/s00520-018-4047-y CrossRefPubMedGoogle Scholar
  13. 13.
    Erickson N, Schaller N, Berling-Ernst AP, Bertz H (2016) Ernährungspraxis Onkologie: Behandlungsalgorithmen, Interventions-Checklisten, Beratungsempfehlungen – griffbereit. Schattauer, StuttgartGoogle Scholar
  14. 14.
    Solheim TS, Laird BJA, Balstad TR et al (2017) A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 8:778–788.  https://doi.org/10.1002/jcsm.12201 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Werner K, Küllenberg de Gaudry D, Taylor LA et al (2017) Dietary supplementation with n‑3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial. Lipids Health Dis 16:104.  https://doi.org/10.1186/s12944-017-0495-5 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Solís-Martínez O, Plasa-Carvalho V, Phillips-Sixtos G et al (2018) Effect of eicosapentaenoic acid on body composition and inflammation markers in patients with head and neck squamous cell cancer from a public hospital in Mexico. Nutr Cancer 70:663–670.  https://doi.org/10.1080/01635581.2018.1460678 CrossRefPubMedGoogle Scholar
  17. 17.
    Jatoi A, Qin R, Satele D et al (2016) “Enjoy glass of wine before eating”: a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Support Care Cancer 24:3739–3746.  https://doi.org/10.1007/s00520-016-3190-6 CrossRefPubMedGoogle Scholar
  18. 18.
    Sun D, Jiao J, Zhang X et al (2015) Therapeutic effect of Jinlongshe Granule on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: A double-blind placebo-controlled clinical trial. Chin J Integr Med 21:579–586.  https://doi.org/10.1007/s11655-014-1950-z CrossRefPubMedGoogle Scholar
  19. 19.
    Chung VCH, Wu X, Lu P et al (2016) Chinese herbal medicine for symptom management in cancer palliative care: systematic review and meta-analysis. Medicine (Baltimore) 95:e2793.  https://doi.org/10.1097/MD.0000000000002793 CrossRefGoogle Scholar
  20. 20.
    Lau CHY, Wu X, Chung VCH et al (2016) Acupuncture and related therapies for symptom management in palliative cancer care. Medicine (Baltimore).  https://doi.org/10.1097/MD.0000000000002901 CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Yoon SL, Grundmann O, Williams JJ, Carriere G (2015) Novel intervention with acupuncture for anorexia and cachexia in patients with gastrointestinal tract cancers: a feasibility study. Oncol Nurs Forum 42:E102–E109.  https://doi.org/10.1188/15.ONF.E102-E109 CrossRefPubMedGoogle Scholar
  22. 22.
    Ohnishi S, Watari H, Kanno M et al (2017) Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). J Gynecol Oncol 28:e44.  https://doi.org/10.3802/jgo.2017.28.e44 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hamai Y, Yoshiya T, Hihara J et al (2019) Traditional Japanese herbal medicine rikkunshito increases food intake and plasma acylated ghrelin levels in patients with esophageal cancer treated by cisplatin-based chemotherapy. J Thorac Dis 11:2470–2478.  https://doi.org/10.21037/jtd.2019.05.67 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cheon C, Yoo J‑E, Yoo H‑S et al (2017) Efficacy and safety of Sipjeondaebo-tang for anorexia in patients with cancer: a pilot, randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med.  https://doi.org/10.1155/2017/8780325 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mücke M, Weier M, Carter C et al (2018) Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle 9:220–234.  https://doi.org/10.1002/jcsm.12273 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D et al (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 26:3029–3038.  https://doi.org/10.1007/s00520-018-4154-9 CrossRefPubMedGoogle Scholar
  27. 27.
    Palma CGL, Lera AT, Lerner T et al (2016) Guarana (Paullinia cupana) improves anorexia in patients with advanced cancer. J Diet Suppl 13:221–231.  https://doi.org/10.3109/19390211.2015.1008612 CrossRefPubMedGoogle Scholar
  28. 28.
    Huebner J, Freuding M, Keinki C et al (2019) Answer to the letter to the editors by Matthes and colleagues regarding our systematic reviews on mistletoe. J Cancer Res Clin Oncol.  https://doi.org/10.1007/s00432-019-02979-z CrossRefPubMedGoogle Scholar
  29. 29.
    Freuding M, Keinki C, Micke O et al (2019) Mistletoe in oncological treatment: a systematic review. Part 1: survival and safety. J Cancer Res Clin Oncol 145:695–707.  https://doi.org/10.1007/s00432-018-02837-4 CrossRefPubMedGoogle Scholar
  30. 30.
    Freuding M, Keinki C, Kutschan S et al (2019) Mistletoe in oncological treatment: a systematic review. Part 2: quality of life and toxicity of cancer treatment. J Cancer Res Clin Oncol 145:927–939.  https://doi.org/10.1007/s00432-018-02838-3 CrossRefPubMedGoogle Scholar
  31. 31.
    Pahlow M (2004) Das große Buch der Heilpflanzen: Gesund durch die Heilkräfte der Natur. Weltbild, AugsburgGoogle Scholar
  32. 32.
    Achmüller A (2018) Verdauung und Entschlackung: Kraut und Wurzel. Edition Raetia, BozenGoogle Scholar
  33. 33.
    Schönfelder I, Schönfelder P (2019) Der Kosmos Heilpflanzenführer. Kosmos, StuttgartGoogle Scholar
  34. 34.
    Mayer JG, Uehleke B, Saum K (2013) Das große Buch der Klosterheilkunde: Neues Wissen über die Wirkung der Heilpflanzen. Vorbeugen, behandeln und heilen. Zabert Sandmann, HamburgGoogle Scholar
  35. 35.
    Niederegger O, Mayr C (2005) Hausbuch der Südtiroler Heilkräuter: Gesundheit aus der Natur, 1. Aufl. Athesia Tappeiner, BolzanoGoogle Scholar
  36. 36.
    Adler M (2010) Lehrbuch Naturheilverfahren: 106 Tabellen. Thieme, StuttgartGoogle Scholar
  37. 37.
    Hohenberger E (2010) Gewürzkräuter und Heilpflanzen: 89 Gartenkräuter. Anbau, Ernte, Aufbereitung, Inhaltsstoffe, Verwendung. Obst- und Gartenbauverlag, MünchenGoogle Scholar
  38. 38.
    Thoms H (2015) Altes Kräuterwissen aus dem Harz. Bussert + Stadeler, QuedlinburgGoogle Scholar
  39. 39.
    Hecker F, Hecker K (2019) Heilsame Wildpflanzen: im Rhythmus der 10 Jahreszeiten sammeln und anwenden. Haupt, BerlinGoogle Scholar
  40. 40.
    Rätsch C (2014) Heilpflanzen der Antike: Mythologie, Heilkunst und Anwendung. AT, AarauGoogle Scholar
  41. 41.
    Achmüller A (2012) Teufelskraut, Bauchwehblüml, Wurmtod: das Kräuterwissen Südtirols. Mythologie, Volksmedizin und wissenschaftliche Erkenntnisse. Edition Raetia, BozenGoogle Scholar
  42. 42.
    Salem A, Mistry H, Hatton M et al (2019) Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer: secondary analysis of a randomized clinical trial. JAMA Oncol 5:e185335.  https://doi.org/10.1001/jamaoncol.2018.5335 CrossRefPubMedGoogle Scholar
  43. 43.
    Bar-Ad V, Ohri N, Werner-Wasik M (2012) Esophagitis, treatment-related toxicity in non-small cell lung cancer. Rev Recent Clin Trials 7:31–35CrossRefGoogle Scholar
  44. 44.
    Soni PD, Boonstra PS, Schipper MJ et al (2017) Lower incidence of esophagitis in the elderly undergoing definitive radiation therapy for lung cancer. J Thorac Oncol 12:539–546.  https://doi.org/10.1016/j.jtho.2016.11.2227 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Everitt S, Duffy M, Bressel M et al (2016) Association of oesophageal radiation dose volume metrics, neutropenia and acute radiation oesophagitis in patients receiving chemoradiotherapy for non-small cell lung cancer. Radiat Oncol 11:20.  https://doi.org/10.1186/s13014-016-0596-8 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Wang T, Yu J, Liu M et al (2019) The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies. Drug Des Devel Ther 13:539–553.  https://doi.org/10.2147/DDDT.S189514 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hu X, He W, Wen S et al (2016) Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A meta-analysis. Plos One 11:e151988.  https://doi.org/10.1371/journal.pone.0151988 CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Onuki T, Morita E, Sakamoto N et al (2018) Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep 6:e334.  https://doi.org/10.1002/rcr2.334 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Baker S, Fairchild A (2016) Radiation-induced esophagitis in lung cancer. Lung Cancer (Auckl) 7:119–127.  https://doi.org/10.2147/LCTT.S96443 CrossRefGoogle Scholar
  50. 50.
    Wu J, Ni M, Zhu J et al (2019) Clinical evaluation of Javanica oil emulsion injection combined with the radiotherapy in the treatment of esophageal cancer: a systematic review and meta-analysis. J Altern Complement Med 25:542–551.  https://doi.org/10.1089/acm.2018.0096 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Chen J, Li L, Zhang D et al (2015) Meta-analysis of javanica oil emulsion injection combined with radiotherapy in the treatment of esophageal carcinoma. J Pract Med 13:2182–2185Google Scholar
  52. 52.
    Zhang D, Ni M, Wu J et al (2019) The optimal Chinese herbal injections for use with radiotherapy to treat esophageal cancer: a systematic review and Bayesian network meta-analysis. Front Pharmacol.  https://doi.org/10.3389/fphar.2018.01470 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Xiao Z, Liang R, Wang C‑Q et al (2016) Can Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer?: A meta-analysis of 16 randomized controlled trials following the PRISMA guidelines. Medicine (Baltimore) 95:e4517.  https://doi.org/10.1097/MD.0000000000004517 CrossRefGoogle Scholar
  54. 54.
    Pollock AE, Shinn L, Anderson R et al (2018) Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update. Lung Cancer (Auckl) 9:79–84.  https://doi.org/10.2147/LCTT.S155315 CrossRefGoogle Scholar
  55. 55.
    Devine A, Marignol L (2016) Potential of amifostine for chemoradiotherapy and radiotherapy-associated toxicity reduction in advanced NSCLC: a meta-analysis. Anticancer Res 36:5–12PubMedGoogle Scholar
  56. 56.
    Sayles C, Hickerson SC, Bhat RR et al (2016) Oral glutamine in preventing treatment-related mucositis in adult patients with cancer. Nutr Clin Pract 31:171–179.  https://doi.org/10.1177/0884533615611857 CrossRefPubMedGoogle Scholar
  57. 57.
    Chang S‑C, Lai Y‑C, Hung J‑C, Chang C‑Y (2019) Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer. Medicine (Baltimore) 98:e14463.  https://doi.org/10.1097/MD.0000000000014463 CrossRefGoogle Scholar
  58. 58.
    Fogh SE, Deshmukh S, Berk LB et al (2017) A randomized phase 2 trial of prophylactic Manuka honey for the reduction of chemoradiation therapy-induced esophagitis during the treatment of lung cancer: results of NRG oncology RTOG 1012. Int J Radiat Oncol Biol Phys 97:786–796.  https://doi.org/10.1016/j.ijrobp.2016.11.022 CrossRefPubMedGoogle Scholar
  59. 59.
    Rouëssé J, Huertas D, Sancho-Garnier H et al (1981) 2 N-methyl-9-hydroxy-ellipticine in treatment of metastatic breast cancers. Bull Cancer 68:437–441PubMedGoogle Scholar
  60. 60.
    Niijima T, Koyanagi T, Maru A et al (1986) Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors—Urological Cooperative Study Group of EPI. Hinyokika Kiyo 32:1359–1369PubMedGoogle Scholar
  61. 61.
    Takizawa K, Ino Y, Isono T et al (1987) Side effects and anti-cancer effects following intraperitoneal (ip) administration of mitomycin C (MMC). Gan To Kagaku Ryoho 14:1877–1883PubMedGoogle Scholar
  62. 62.
    Hashimura T, Okumura K, Akao T, Nakagawa T (1991) Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer. Hinyokika Kiyo 37:685–688PubMedGoogle Scholar
  63. 63.
    Taguchi T, Furuse K, Fukuoka M et al (1996) LY188011 phase I study. Research group of gemcitabine (LY188011). Gan To Kagaku Ryoho 23:1011–1018PubMedGoogle Scholar
  64. 64.
    Chiu JW, Hotte SJ, Kollmannsberger CK et al (2016) A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Invest New Drugs 34:104–111.  https://doi.org/10.1007/s10637-015-0313-8 CrossRefPubMedGoogle Scholar
  65. 65.
    Lin J, Zhang W, Xie B et al (2006) Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer. Chin J Lung Cancer 9:455–457.  https://doi.org/10.3779/j.issn.1009-3419.2006.05.14 CrossRefGoogle Scholar
  66. 66.
    Gross M, Higano C, Pantuck A et al (2007) A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7:142.  https://doi.org/10.1186/1471-2407-7-142 CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Suzuki H, Kanou Y, Ooshima H et al (2005) Trial of outpatient anti-cancer chemotherapy with infusion of 5‑FU and cisplatin for advanced gastric and colorectal cancers. Gan To Kagaku Ryoho 32:189–193PubMedGoogle Scholar
  68. 68.
    Kudo M, Ueshima K, Yokosuka O et al (2018) Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 3:424–432.  https://doi.org/10.1016/S2468-1253(18)30078-5 CrossRefPubMedGoogle Scholar
  69. 69.
    Tang L‑Q, Chen D‑P, Guo L et al (2018) Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 19:461–473.  https://doi.org/10.1016/S1470-2045(18)30104-9 CrossRefPubMedGoogle Scholar
  70. 70.
    Jonker DJ, Nott L, Yoshino T et al (2018) Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol 3:263–270.  https://doi.org/10.1016/S2468-1253(18)30009-8 CrossRefPubMedGoogle Scholar
  71. 71.
    Harrington KJ, Ferris RL, Blumenschein G et al (2017) Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 18:1104–1115.  https://doi.org/10.1016/S1470-2045(17)30421-7 CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Twelves C, Cortés J, O’Shaughnessy J et al (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. Eur J Cancer 76:205–215.  https://doi.org/10.1016/j.ejca.2017.02.011 CrossRefPubMedGoogle Scholar
  73. 73.
    Takahashi T, Yamanaka T, Seto T et al (2017) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18:663–671.  https://doi.org/10.1016/S1470-2045(17)30230-9 CrossRefPubMedGoogle Scholar
  74. 74.
    Cirkel GA, Hamberg P, Sleijfer S et al (2017) Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progression in patients with metastatic clear cell renal cell cancer: the ROPETAR randomized clinical trial. JAMA Oncol 3:501–508.  https://doi.org/10.1001/jamaoncol.2016.5202 CrossRefPubMedGoogle Scholar
  75. 75.
    Sugiyama T, Okamoto A, Enomoto T et al (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol 34:2881–2887.  https://doi.org/10.1200/JCO.2016.66.9010 CrossRefPubMedGoogle Scholar
  76. 76.
    Oki E, Murata A, Yoshida K et al (2016) A randomized phase III trial comparing S‑1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). Ann Oncol 27:1266–1272.  https://doi.org/10.1093/annonc/mdw162 CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Fujitani K, Yang H‑K, Mizusawa J et al (2016) Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 17:309–318.  https://doi.org/10.1016/S1470-2045(15)00553-7 CrossRefPubMedGoogle Scholar
  78. 78.
    Hu X‑C, Zhang J, Xu B‑H et al (2015) Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16:436–446.  https://doi.org/10.1016/S1470-2045(15)70064-1 CrossRefPubMedGoogle Scholar
  79. 79.
    Ioka T, Okusaka T, Ohkawa S et al (2015) Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized phase III trial. Jpn J Clin Oncol 45:439–448.  https://doi.org/10.1093/jjco/hyv011 CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Zhu AX, Rosmorduc O, Evans TRJ et al (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:559–566.  https://doi.org/10.1200/JCO.2013.53.7746 CrossRefPubMedGoogle Scholar
  81. 81.
    Shimada Y, Hamaguchi T, Mizusawa J et al (2014) Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205. Eur J Cancer 50:2231–2240.  https://doi.org/10.1016/j.ejca.2014.05.025 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Hämatologie und Medizinische OnkologieUniversitätsmedizin GöttingenGöttingenDeutschland
  2. 2.Klinik für Innere Medizin II (Hämatologie und Internistische Onkologie)Universitätsklinikum JenaJenaDeutschland
  3. 3.Klinik für HNO-Erkrankungen, Kopf-Hals-ChirurgieSüdharz-Klinikum Nordhausen gGmbHNordhausenDeutschland

Personalised recommendations